Apoptosis and Autophagy in Breast Cancer Cells following Exemestane Treatment

Cristina Amaral¹², Margarida Borges¹, Soraia Melo¹³, Elisábio Tavares da Silva⁴, Georgina Correia-da-Silva¹², Natércia Teixeira¹²*

¹ Laboratory of Biochemistry, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal, ² Institute for Molecular and Cell Biology (IBMC), University of Porto, Porto, Portugal, ³ Department of Zoology, Faculty of Sciences and Technology, University of Coimbra, Coimbra, Portugal, ⁴ Center of Pharmaceutical Studies, Pharmaceutical Chemistry Laboratory, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal

Abstract

Aromatase inhibitors (AIs), which block the conversion of androgens to estrogens, are used for hormone-dependent breast cancer treatment. Exemestane, a steroidal that belongs to the third-generation of AIs, is a mechanism-based inhibitor that binds covalently and irreversibly, inactivating and destabilizing aromatase. Since the biological effects of exemestane in breast cancer cells are not totally understood, its effects on cell viability, cell proliferation and mechanisms of cell death were studied in an ER-positive aromatase-overexpressing breast cancer cell line (MCF-7aro). The effects of 3-methyladenine (3-MA), an inhibitor of autophagy and of ZVAD-FMK, an apoptotic inhibitor, in exemestane treated cells were also investigated. Our results indicate that exemestane induces a strong inhibition in MCF-7aro cell proliferation in a dose- and time-dependent manner, promoting a significant cell cycle arrest in G0/G1 or in G2/M phases after 3 and 6 days of treatment, respectively. This was accompanied by a decrease in cell viability due to activation of cell death by apoptosis, via mitochondrial pathway and the occurrence of autophagy. Inhibition of apoptosis by the autophagic inhibitor, 3-MA, resulted in a reduction of cell viability and activation of caspases. All together the results obtained suggest that exemestane induced mitochondrial-mediated apoptosis and autophagy, which act as a pro-survival process regulating breast cancer cell apoptosis.

Introduction

Breast cancer is the most common cause of cancer death in women worldwide. Among breast cancer patients, 60% of pre-menopausal and 70–80% of post-menopausal women have hormone-dependent (estrogen receptor positive [ER⁺]) tumors [1,2]. As estrogens play a crucial role in stimulating ER⁺ tumor growth, the suppression of their effects is considered an important therapeutic target for breast cancer treatment. Two main approaches have been successfully applied. One targets the ER directly through the use of selective estrogen receptor modulators (SERM), such as tamoxifen, or of selective estrogen receptor down-regulators (SERD), like fulvestrant. The other is achieved by the use of aromatase inhibitors (AIs) that inhibit aromatase, the enzyme responsible by the last step of estrogen synthesis, blocking the conversion of androgens to estrogens [1,3].

Over the past three decades AIs became an effective alternative to tamoxifen, showing clinical benefits with high specificity and reduced recurrence rates [4]. The third-generation of AIs includes non-steroidal triazole derivatives, anastrozole and letrozole, that act as competitive inhibitors and one steroidal derivate of androstenedione, exemestane [4,5]. Exemestane is a mechanism-based inhibitor that is catalytically converted into chemically reactive intermediates These molecules bind covalently and irreversibly to the substrate-binding pocket of the enzyme, inactivating and producing suicide aromatase inhibition [1,6,7]. Wang and Chen (2006) found that exemestane destabilizes aromatase and induces its degradation by the proteosome after its irreversible inactivation [8]. On the other hand, exemestane and its principal metabolite, 17-hydroxexemestane, exhibit androgenic effects as it binds with high affinity to the androgen receptor, causing in that way, lower bone loss [2,6,7].

The efficacy of hormonal therapy in breast cancer is based on the fact that estrogens play an important role in cancer cell survival and proliferation, essentially affecting cell cycle [9] and inducing expression of growth factors and cytokines [10,11]. It has also been reported that estrogen deprivation causes a decrease in cell proliferation and induces apoptosis in MCF-7 cells [12,13] and in MCF-7 xenografts [14,15]. SERMs [13,16,17] and antagonists of estrogen receptor [18] induce inhibition of cell proliferation and apoptosis in breast cancer cell lines. Although recent reports showed that tamoxifen and 4-hydroxytamoxifen (4-OHT) induced autophagy [19,20], others referred that tamoxifen treatment is associated with both types of cell death [21,22]. It has also been reported that some AIs, like letrozole, anastrozole and formestane inhibit proliferation of breast cancer cells by inducing cell cycle
arrest in $G_0/G_1$ phase and cell death by apoptosis [13,23]. Recently, we demonstrated that the steroidal AIs $5\alpha$-androst-3-en-17-one and $3\alpha,4\alpha$-epoxy-$5\alpha$-androstan-17-one, previously synthesized in our laboratory [24], inhibit cell proliferation in various tumour cell lines [25] and induce apoptosis and autophagy in MCF-7aro cell line [26]. Nevertheless, the effects of exemestane in breast cancer cells are not totally understood. In this way, it was evaluated the biological effects of this steroidal AI in an ER-positive aromatase-overexpressing breast cancer cell line (MCF-7aro) and studied the mechanisms of cell death induced by exemestane.

Results

Morphological studies

To investigate the morphological alterations induced by exemestane, MCF-7aro cells, were cultured with or without exemestane during 3, 6 (Fig. 1) and 9 days and examined by phase contrast microscopy, Giemsa and Hoechst staining. After 3 days of exemestane treatment, few membrane blebbings and chromatin fragmentation were observed (data not shown). After 6 and 9 days, cells showed marked morphological alterations, like membrane blebbings, chromatin condensation and fragmentation, cytoplasm vacuolization and the presence of non-adherent cells. A decrease in cell density was also observed after 9 days of treatment (data not shown). These features were more evident for the highest concentration of exemestane and increased with the time of treatment.

Cell viability and cell proliferation

To evaluate the effects of exemestane (2.5–15 μM) in MCF-7aro cells viability and cytotoxicity, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) and lactate dehydrogenase (LDH) assays were performed for 2, 3, 6 and 9 days. After 2 days of exemestane treatment no effects in cell viability were observed. Although, after 3, 6 and 9 days and as shown in Fig. 2A, exemestane induced a reduction in cell viability that was dose- and time-dependent. The lower concentrations of exemestane (2.5–5 μM) did not affect cell viability, except in the case of 9 days of treatment. However, for the higher concentrations (10–15 μM), exemestane induced a significant decrease ($p<0.05$; $p<0.001$) in cell viability. A significant increase ($p<0.05$) in LDH release was only observed for exemestane at 15 μM after 9 days of treatment (Fig. 2B).

To analyse the exemestane effects in cell proliferation, thymidine incorporation assay was performed. As shown in Fig. 2C, exemestane induced a dramatic decrease in cell proliferation in a dose- and time-dependent manner. Contrary to the effect on cell viability, all concentrations and times of incubation caused a statistically significant decrease ($p<0.05$; $p<0.001$) in the rate of DNA synthesis.

Cell cycle analysis

To identify the underlying mechanism associated with the anti-proliferative effects of exemestane, it was evaluated the effect on cell cycle progression by measuring DNA content by flow cytometry. After 3 days of treatment, different concentrations of

![Figure 1. Effects of exemestane on MCF-7aro cells morphology.](https://example.com/figure1.png)
exemestane (5–10 μM) caused a significant cell cycle arrest in G_0/ G_1 phase and a decrease in the percentage of cells in S and G_2/M cell cycle phases (Fig. 2D) in a dose-dependent manner. An accumulation of cells in G_0/G_1 phase of 73.39±1.25%, 81.94±0.23% (p<0.001) and 90.30±1.68% (p<0.001) was observed for 2.5, 5 and 10 μM, respectively, when comparing to the control (70.49±1.37%). However, after 6 days of treatment it was detected an arrest in G_2/M phase, 20.43±1.05% (p<0.005) and 34.47±2.67% (p<0.001) for 5 and 10 μM, respectively, when comparing to the control 14.56±0.34% (Fig. 2E).

### Analysis of cell death

To investigate the type of cell death induced by exemestane in MCF-7aro cells, assays for apoptosis and autophagy assessment were performed. For the apoptotic analysis, translocation of PS to the outer surface of plasma membrane was evaluated by Annexin V-PE binding (Fig. 3A) (Table 1). After 3 days of treatment, no differences were detected when comparing to control (data not shown). However, after 6 days, exemestane at 10 and 15 μM induced a significant increase of approximately 2.67 (p<0.005) for 2.5, 5 and 10 μM, respectively, when comparing to the binding to Annexin V (70.49±1.37%). However, after 6 days of treatment it was detected an arrest in G_2/M phase, 20.43±1.05% (p<0.005) and 34.47±2.67% (p<0.001) for 5 and 10 μM, respectively, when comparing to the control 14.56±0.34% (Fig. 2E).

After 6 days of treatment, a higher and significant (p<0.001) increase of ∆Ψm loss, approximately 21 times, was detected for both concentrations. Thus, the ∆Ψm loss was only time-dependent.

Since mitochondrial membrane depolarization can lead to activation of caspase-9, it was evaluated caspase-9 activity by a luminescent assay. After 3 days of incubation, a significant increase (p<0.05) of approximately 67.77% (5645±191.8 relative luminescence units (RLU) and 66.23% (5793±398 RLU) was detected for 10 and 15 μM, respectively, in comparison to control (3484±459.0) (Fig. 4A). Caspase-8 activity was also determined and no significant differences were obtained after 3 days of treatment (Fig. 4B). Since there was a significant activation of caspase-9 it was also evaluated the activation of the effector caspase-7. After exemestane treatment there was a significant increase (p<0.01) of approximately 45.01% (3824±228.5 RLU) and 48.35% (3912±234.0 RLU) for 10 and 15 μM, respectively, in comparison to control (2637±161.3) (Fig. 4C).

Once the appearance of intracellular reactive oxygen species (ROS) may also be correlated with mitochondria dysfunction, it was evaluated the presence of ROS after 3 days of treatment, by the use of 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA). A significant increase (p<0.01) production of 25.41% (13626±624.8 MFI) and 21.52% (13920±437.91 mean fluorescence intensity (MFI)) was detected for 10 and 15 μM of exemestane, respectively, when compared to control (10685±561.54 MFI) (Fig. 4D).

In order to clarify the nature of the cytoplasmatic vacuoles observed in contrast phase microscopy and Giemsa staining, acridine orange (AO), an acridotopic dye, was used. The lysosomotropic and pH-sensitive AO detects acid vesicular organelles (AVOs) [27], suggesting the occurrence of autophagy. AO is a cell-permeable fluorescent dye that moves freely across biological membranes and stains DNA and cytoplasm bright green. In acid compartments, such as lysosomes and autolysosomes, AO is protonated and accumulates, forming aggregates that fluorescence bright red [27,28]. By flow cytometry analysis...
(Table 3), it was observed, after 3 days of treatment, an increase in AVOs formation (AO+) about 2 to 3.5 times (p<0.001) higher than control. Similar results were observed after 6 and 9 days. In addition, it was also detected the presence of AVOs by fluorescence microscopy. In treated cells and for all time points, it was observed alterations in green fluorescence to yellow/orange/red fluorescence that increased with exemestane concentration and time of exposure (Fig. 5A).

The presence of autophagosomes was confirmed by electron microscopy. After 6 days exposure to exemestane treatment (15 μM) (Fig. 5B), ultrastructural analysis revealed typical morphological features of autophagy, like giant autophagosomes in the cytoplasm, containing remnant organelles including mitochondria.

The presence of microtubule-associated protein 1 light chain 3 (LC3) protein, an autophagic marker, in cells treated with exemestane was also evaluated by immunoblotting (Fig. 5C). The autophagosome formation can be evaluated by the conversion of LC3-I to LC3-II [27]. After 3 days, exemestane-treated cells presented higher levels of LC3-II than LC3-I, confirming the presence of autophagosomes.

Effects of autophagic and apoptotic inhibitors in MCF-7aro cells treated with exemestane

As MCF-7aro cells treated with the higher concentrations of exemestane (10 and 15 μM), presented autophagic features, like cytoplasm vacuolization and an increase of AVOs, the effects of the autophagic inhibitor 3-methyladenine (3-MA) were investigated.

When cells were treated with exemestane plus 3-MA during 3 and 6 days, it was observed a reduction in cytoplasmatic vacuolization. Moreover, the autophagic inhibitor induced a significant (p<0.01) reduction in cell viability after 3 days (88.17±2.58% to 71.67±1.25% for 10 μM and of 72.93±1.85% to 65.82±1.33% for 15 μM of exemestane without or with 3-MA, respectively) and 6 days of treatment (68.51±3.76% to 55.73±1.92% for 10 μM and of

| Table 1. Effects of exemestane on Annexin V-PE labelling in MCF-7aro cells. |
| --- |
| 6 DAYS | T | T+5 μM | T+10 μM | T+15 μM | T+STS 1 μM |
| Annexin V-7-AAD- | 86.69±1.62 | 84.45±0.15 | 74.47±2.53* | 73.24±3.44 | 59.87±1.08*** |
| Annexin V-/7-AAD- | 3.67±0.35 | 5.62±0.45 (1.53) | 9.80±0.92** (2.67) | 10.04±0.61*** (2.74) | 17.40±1.15*** (4.74) |
| Annexin V+/7-AAD* | 9.65±1.28 | 9.94±0.30 (1.03) | 15.57±1.65 (1.61) | 16.73±2.85 (1.73) | 20.38±2.10** (2.11) |
| 9 DAYS | T | T+5 μM | T+10 μM | T+15 μM | T+STS 1 μM |
| Annexin V-/7-AAD- | 83.83±1.22 | 68.98±3.42** | 65.55±3.55** | 60.85±2.65*** | 58.85±5.25*** |
| Annexin V+/7-AAD* | 5.96±0.57 | 11.85±1.84* (1.99) | 12.57±1.07** (2.11) | 15.78±1.65*** (2.65) | 21.09±1.71*** (3.54) |
| Annexin V+/7-AAD* | 9.99±1.02 | 19.18±2.11* (1.92) | 21.88±2.85** (2.19) | 27.79±0.87*** (2.78) | 20.61±3.94* (2.06) |

Cells were treated with different concentrations of exemestane for 6 and 9 days. Treated cells were harvested and labeled with Annexin V-PE and 7-AAD followed by flow cytometry analysis. Data are presented as viable cells (Annexin V-/7-AAD-); early apoptotic (Annexin V+/7-AAD-) and late apoptotic or necrotic cells (Annexin V+/7-AAD+). Cells cultured with T at 1 nM were considered as control and cells treated with T plus STS (1 μM) were considered as positive control for apoptosis. The data represents mean ± SEM of three independent experiments done in triplicate. The ratio treatment/control is presented in bold within brackets. Significant differences between the control versus treated cells are indicated by

* (p<0.05), ** (p<0.01) and *** (p<0.001).

doi:10.1371/journal.pone.0042398.t001

Figure 3. Annexin V-PE labeling and mitochondrial transmembrane potential following exemestane treatment. (A) Annexin V-PE labeling of MCF-7aro cells treated with exemestane (15 μM) for 6 and 9 days of treatment. Cells cultured with T were considered as control and for 6 days present 3.54% and for 9 days 5.58% of Annexin V binding. Data presented in histograms were analysed with FlowJo Software (Tree Star, Inc), correspond to cells gated for negative 7-AAD staining and are representative of one independent assay. The grey filled line corresponds to control and the black line to exemestane at 15 μM. (B) Mitochondrial transmembrane potential (ΔΨm) of MCF-7aro cells treated with exemestane (15 μM) with or without 3-MA (1 mM), for 3 and 6 days. Viable cells and cells with ΔΨm loss were identified. Data presented in histograms were analysed with FlowJo Software (Tree Star, Inc) and are representative of one independent assay.

doi:10.1371/journal.pone.0042398.g003
59.28±3.79% to 46.75±2.94% for 15 μM of exemestane without or with 3-MA, respectively).

By the analysis of Annexin V-PE assay, after 6 days, any difference between exemestane with or without 3-MA (data not show) was observed, suggesting that 3-MA, in the conditions used, did not affect the translocation of PS to the outer surface of plasma membrane caused by exemestane at that time point. However, 3-MA induced a decrease in the ΔΨm loss of cells treated with exemestane (Table 2) (Fig. 3B). Comparing the ratio treatment/control of ΔΨm loss for both days, it was noted that this reduction was only dependent on time and not on exemestane concentration. In addition, in our conditions, 3-MA only induced a slight decrease of approximately 10% in the caspase-9 activity after 3 days of exemestane treatment (Fig. 4A). However, exemestane plus 3-MA induced a significant increase (p<0.05) of 37.52% (3489±235.8 RLU) and 59.62% (3615±306.3 RLU) in caspase-8 activity for 10 and 15 μM, respectively (Fig. 4B) and also a significant increase (p<0.001) in caspase-7 activity of 72.30% (4628±86.02 RLU) and 69.69% (4558±142.5 RLU) for 10 and 15 μM, respectively (Fig. 4C), when compared to control. The cells treated with exemestane plus 3-MA presented a significant increase (p<0.05) in caspase-8 and caspase-7 activity (Fig. 4B, 4C), when comparing to exemestane-treated cells.

Inhibition of autophagy at day 6 by 3-MA almost completely abolished the AO positive staining induced by exemestane. When cells were exposed to 3-MA plus exemestane, the AVOs formation decreased to 19.61% versus 32.91% for only exemestane, respectively (Fig. 4D) and also a significant increase (p<0.001) in caspase-7 activity of 72.30% (4628±86.02 RLU) and 69.69% (4558±142.5 RLU) for 10 and 15 μM, respectively (Fig. 4C), when compared to control. The cells treated with exemestane plus 3-MA presented a significant increase (p<0.05) in caspase-8 and caspase-7 activity (Fig. 4B, 4C), when comparing to exemestane-treated cells.

**Table 2. Effects of exemestane on mitochondrial transmembrane potential (ΔΨm) in MCF-7aro cells.**

| 3 DAYS | T | T+10 μM | T+15 μM | T+CCC 10 μM |
|--------|---|---------|---------|-------------|
| Viable | 94.58±1.05 | 32.37±2.71*** | 28.63±2.90*** | 35.88±3.86*** |
| ΔΨm loss | 5.49±1.06 | 67.80±2.73*** (12.35) | 71.59±2.90*** (13.04) | 65.06±4.21*** (11.85) |
| T+3-MA | | | |
| Viable | 88.88±3.60 | 39.42±0.06*** | 36.89±4.42*** | - |
| ΔΨm loss | 11.23±3.63 | 60.80±1.85*** (5.41) | 63.51±4.51*** (5.66) | - |
| 6 DAYS | T | T+10 μM | T+15 μM | T+CCC 10 μM |
| Viable | 95.77±0.08 | 22.01±3.04*** | 20.75±2.07*** | 30.43±4.32*** |
| ΔΨm loss | 3.65±0.13 | 77.85±2.77*** (21.33) | 79.07±2.06*** (21.66) | 68.49±4.74*** (18.76) |
| T+3-MA | | | |
| Viable | 90.51±2.80 | 32.07±3.14*** | 28.02±1.86*** | - |
| ΔΨm loss | 8.50±2.28 | 67.84±3.45*** (7.98) | 71.71±2.26*** (8.44) | - |

Cells were treated with different concentrations of exemestane with or without 1 mM of 3-MA after 3 and 6 days. Treated cells were harvested and labeled with DiOC6(3) and PI followed by flow cytometry analysis. Data are presented as viable cells and cells with ΔΨm loss. Cells cultured with T were considered as control and cells treated with T plus CCCP (10 μM) were considered as positive control for ΔΨm loss. The data represents means ± SEM of three independent experiments done in triplicate. The ratio treatment/control is presented in bold within brackets. Significant differences between the control versus treated cells, or between the control plus 3-MA versus cells with exemestane plus 3-MA are indicated by *** (p<0.001).

**Figure 4. Activation of caspases and ROS production.** Caspase-9 (A), caspase-8 (B) and caspase-7 (C) activities of MCF-7aro cells treated with exemestane after 3 days. The effects of 3-MA on caspase activities were also studied. Cells cultured with T were considered as control, cells treated with STS were considered as positive control and with Z-VAD-FMK was negative control. The results are presented as relative luminescence units (RLU). (D) ROS in MCF-7aro cells treated with exemestane after 3 days. It was also studied the effects of 3-MA. Cells cultured with T were considered as control and cells treated with PMA were as positive control for ROS production. The results are presented as mean fluorescence intensity (MFI). Results are the mean ± SEM of three independent experiments performed in triplicate. Significant differences between the control T versus treated cells, or between the control plus 3-MA versus cells with exemestane plus 3-MA are indicated by * (p<0.05), ** (p<0.01) and *** (p<0.001); between the cells treated with exemestane versus cells with exemestane plus 3-MA are indicated by # (p<0.05); between the cells treated with exemestane versus cells with exemestane plus Z-VAD-FMK are indicated by ## (p<0.01).
Table 3. Quantification of acid vesicular organelles (AVOs) in MCF-7aro cells treated with exemestane.

|          | Testosterone | T+10 µM | T+15 µM | T+H₂O₂ |
|----------|--------------|---------|---------|---------|
| AO       | 86.53±0.80   | 68.83±1.02*** | 52.09±1.99*** | 25.91±2.86*** |
| AO*      | 13.63±0.77   | 31.40±1.05*** (2.30) | 48.25±2.01*** (3.54) | 74.65±2.97*** (5.48) |

|          | T+3-MA | T+10 µM+3-MA | T+15 µM+3-MA |
|----------|--------|--------------|--------------|
| AO       | 78.48±3.95   | 51.57±4.03*** | 38.06±0.58*** |
| AO*      | 22.17±4.10   | 49.88±4.48*** (2.25) | 62.04±0.67*** (2.80) |

|          | Testosterone | T+10 µM | T+15 µM | T+H₂O₂ |
|----------|--------------|---------|---------|---------|
| AO       | 78.70±1.62   | 40.93±2.66*** | 25.68±1.18*** | 24.62±3.74*** |
| AO*      | 21.51±1.62   | 59.35±2.66*** (2.76) | 74.21±1.62*** (3.45) | 75.38±3.78*** (3.50) |

|          | T+3-MA | T+10 µM+3-MA | T+15 µM+3-MA |
|----------|--------|--------------|--------------|
| AO       | 76.47±2.01   | 80.61±1.75*** | 72.23±1.64*** |
| AO*      | 23.77±2.02   | 19.61±1.79*** (0.82) | 27.52±1.17*** (1.16) |

|          | Testosterone | T+10 µM | T+15 µM | T+H₂O₂ |
|----------|--------------|---------|---------|---------|
| AO       | 67.23±2.55   | 31.48±2.97*** | 26.11±1.24*** | 21.43±3.52*** |
| AO*      | 33.20±2.64   | 68.80±2.96*** (2.07) | 73.88±1.37*** (2.23) | 82.65±3.82*** (2.49) |

Cells were treated with different concentrations of exemestane after 3, 6 and 9 days. Cells with 50 µM of zVAD or with 1 mM of 3-MA, with or without exemestane (5–15 µM), were also studied for 3 and 6 days, respectively. Treated cells were harvested, stained with acridine orange and analyzed by flow cytometry. Data are presented as single cell events of viable cells, AO negative (AO⁻), and with AVO formation, AO positive (AO⁺). Cells cultured with T were considered as control and cells treated with T and H₂O₂ (0.05 mM) were considered as positive control for autophagic cell death. The data represents means ± SEM of three independent experiments done in triplicate. The ratio treatment/control is presented in bold within brackets. Significant differences between the control versus treated cells, or between the control plus zVAD versus cells with exemestane plus zVAD, or between the control plus 3-MA versus cells with exemestane plus 3-MA are indicated by *** (p<0.001); cells with exemestane versus exemestane plus 3-MA are indicated by ### (p<0.001).

doi:10.1371/journal.pone.0042398.t003

Table 3 shows the quantification of acid vesicular organelles (AVOs) in MCF-7aro cells treated with exemestane. Statistically significant differences were observed between cells with exemestane and cells with exemestane plus 3-MA (p<0.001). The fluorescence microscopy showed that cells treated with exemestane plus 3-MA presented less yellow/orange/red fluorescence (Fig. 5A) than exemestane-treated cells, confirming the reduction of AVOs formation. In cells treated with exemestane during 3 days, it was detected the presence of LC3-II. In the control and treated cells with

Figure 5. Exemestane and autophagy. (A) Effects of exemestane in the formation of AVOs analysed by fluorescence microscopy. MCF-7aro cells were treated with exemestane with or without 3-MA, during 6 days and stained with AO. The presence of AVOs was indicated by the yellow/orange/red fluorescence. (B) Ultrastructural features of cell death in MCF-7aro cells treated with exemestane for 6 days. The presence of autophagosomes (black arrows) was observed in the cytoplasm of treated cells. (C) Western Blot analysis of LC3-I/LC3-II. Cells were cultured with exemestane and with exemestane plus 3-MA for 3 days. β-tubulin was used as a loading control. Cells cultured with T were considered as control. Results are shown from a single representative of three independent experiments.

doi:10.1371/journal.pone.0042398.g005
induction of apoptosis. Activation of the effector caspase-7 by exemestane confirms the evaluated, though no significant increase was detected. The caspase-9 activity and a significant production of intracellular after 3 days of treatment, cells presented a significant increase in translocated to autophagosome membranes to the form LC3-II, converted in the cytosolic form of LC3-I, that is lipidated and mitochondria. During autophagy, the pro-LC3 is proteolytically induced a significant increase in AVOs with the time of exposure. 

Discussion
This study explored the in vitro effects of exemestane on MCF-7aro cell proliferation, cell cycle progression and induction of cell death. This cell line is considered an important tool to study growth responses to aromatase inhibitors, as it is a breast cancer ER+ cell line stably transfected with the aromatase gene, that express high aromatase levels [23]. In the present work, exemestane induced a decrease in MCF-7aro cell proliferation and viability in a dose- and time-dependent manner, with no effects on cell membrane integrity, except for the higher concentration and for prolonged times of exposure. Our results revealed that the anti-proliferative effects of exemestane are essentially due to the retention in G0/G1 phase, which blocks the G1/S phase transition of cell cycle, preventing cells to enter in the S phase that occurs when cells are exposed to exemestane for a short period of time. However, for longer times, exemestane caused retention in G2/M cell cycle phase that has been referred to be associated with enhanced apoptosis and cytotoxicity [29].

Like exemestane, non-steroidal AIs, letrozole and anastrozole, also induced a decrease in cell proliferation and cell cycle arrest in MCF-7aro cells [13,23].

In addition to inhibit cell cycle progression, exemestane caused a reduction in cell viability. This was accompanied by morphological alterations, such as membrane blebbings, chromatin condensation and fragmentation, which suggested the occurrence of cell death by apoptosis. However, the appearance of cytoplasm vacuolization, as well as the presence of AVOs also indicated the occurrence of autophagy.

To clarify the mechanism of cell death involved, it was further studied the effect of exemestane on the exposure of PS to the outer leaflet of cell membrane and on the ΔΨm. Our results revealed that exemestane induced a significant increase in the binding of annexin V and a significant increase in ΔΨm loss. In the intrinsic pathway of apoptosis, a loss of ΔΨm is associated with the release of cytochrome c in the cytosol and formation of apoptosome, leading to the activation of caspase-9 and of effector caspases [30]. After 3 days of treatment, cells presented a significant increase in caspase-9 activity and a significant production of intracellular ROS, suggesting the induction of apoptosis through the activation of the intrinsic pathway. However, as it has been referred that non-steroidal AIs like letrozole and anastrozole induced, respectively, a down-regulation and up-regulation of caspase-8 expression in MCF-7aro cells [23], the activity of this enzyme was also evaluated, though no significant increase was detected. The activation of the effector caspase-7 by exemestane confirms the induction of apoptosis.

In addition, by flow cytometry it was observed that exemestane induced a significant increase in AVOs with the time of exposure. Moreover, electron microscopy revealed the presence of autophagosomes engulfing cytoplasmatic fractions and organelles, such as mitochondria. During autophagy, the pro-LC3 is proteolytically converted in the cytosolic form of LC3-I, that is lipidated and translocated to autophagosome membranes to the form LC3-II, which is associated to the maturation of autophagosomes [27,31]. The AI also induced the turnover of LC3, which is associated to the conversion of LC3-I in LC3-II. All together, our findings confirmed the existence of autophagosomes and suggest the occurrence of autophagy that seems to increase with time of treatment.

As it is referred in the literature that there is a cross-talk between these two types of cell death and some features found in apoptosis, like ΔΨm loss, chromatin condensation and PS exposure to the outer leaflet of cell membrane, may also occur in the autophagic process [32,33], it was evaluated the effects of 3-MA in exemestane treated cells. 3-MA is an inhibitor of autophagy, which blocks the formation of autophagosomes, by controlling class I and class III phosphatidylinositol 3-kinases (PI3K) [27,31]. As expected, the autophagic inhibitor caused a reduction in the cytoplasm vacuolization. 3-MA did neither affect the translocation of PS to the outer surface of plasma membrane nor the increase in the caspase-9 activity induced by exemestane. 3-MA did not completely abolish the drop of ΔΨm, it only reduced the mitochondrial membrane depolarization observed with exemestane, indicating that this phenomenon is due to both processes. On the other hand, cells treated with exemestane plus 3-MA presented an increase in intracellular ROS when comparing to exemestane treated cells. Thus, autophagy may be a defense mechanism against the accumulation of ROS. Autophagy may remove ROS-generating mitochondria, therefore decreasing ROS production, acting as a self-protective mechanism [34]. Moreover, the inhibition of the autophagic process induced a decrease in cell viability and an increment on caspase-8 activity, when compared to exemestane treated cells. Hou et al. (2011) showed that in cytoprotective autophagy, active caspase-8 is sequestered by autophagosomes and degraded by lysosomes [35]. The activity of caspase-8 controls the switch from protective to destructive role of autophagy [32]. Some reports, have demonstrate that activation of caspase-8 may be independent of death receptors activation and occur downstream of mitochondria by a mechanism not totally understood [36,37]. The cytoprotective role of autophagy was confirmed by the significant increase in caspase-7 activity observed in cells treated with exemestane plus 3-MA. Thus, the use of the 3-MA, as shown by a dramatic reduction of AVOs and LC3 II formation, affected the machinery of autophagy, reducing the appearance of the typical features of this process and not the apoptotic markers, like Annexin V or caspase-9. However, it increased the production of ROS and the activation of caspase-8 and caspase-7 in treated cells.

On the other hand, the use of Z-VAD-FMK did not affect the autophagic process. Supporting these observations, Boya et al. (2005) have also demonstrated that Z-VAD-FMK did not affect the formation of autophagic vacuoles by hydroxychloroquine [38].

Different interactions between apoptosis and autophagy have been proposed. They may act as partners to induce efficient cell death in a coordinated or cooperative manner, but in this case, if one pathway of cell death is blocked the other assume or may only be activated if the other fails. Autophagy may act as an antagonist to block apoptotic cell death by promoting cell survival and stabilizing genome integrity. Autophagy may also act as enabler of apoptosis, as it does not lead to death but participates in morphologic and cellular events that occur during apoptosis that should be prevented if autophagy is inhibited [39,40]. In our study, and in the conditions used, when apoptosis is inhibited there is no exacerbation or activation of the other mechanism. However, autophagy inhibition reduced cell viability, increased ROS production and induced activation of caspase-8 and caspase-7. Thus, it appears that autophagy induced by exemestane may act as a pro-survival process. Other authors have demonstrated that
tamoxifen induced both processes of cell death and that autophagy acts as a mechanism of cell pro-survival [20,21]. Recent works in breast cancer cell lines, also showed that autophagy induced by epirubicin [41] or sulforahane [42] acts as pro-survival mechanism, protecting cells from apoptotic cell death. Moreover, Abedin et al. (2007) suggested that the role of autophagy in delaying apoptosis or prolonging survival is characteristic of noninvasive breast tumor cells [43].

In cells with caspase-dependent apoptosis, autophagy can be activated by mitochondrial membrane potential loss and cytochrome c redistribution [44,45], eliminating damaged mitochondria and thereby limiting ROS production and tumor cell death by apoptosis [34,46], being together with apoptosis important for tumor suppression [47].

This is the first study that documents the biological effects and mechanisms of cell death induced by the steroidal AI exemestane, in a breast cancer cell line. The main effect of exemestane on MCF-7aro cells is on cell proliferation due to a significant cell cycle arrest in G0/G1 phase and G2/M. Moreover in the conditions used, autophagy and mitochondrial-mediated apoptosis occur simultaneously. In addition, the mitochondria have an important role in the occurrence of cell death, but autophagy may act as a pro-survival process regulating or controlling breast cancer cells from apoptosis. This study may also suggest the use of inhibitors of autophagy with exemestane in a combination therapy to sensitize breast cancer cells to death, being a promising approach for the treatment of hormone-dependent breast cancers.

Materials and Methods

Cell culture

The ER-positive aromatase-overexpressing human breast cancer cell line, MCF-7aro, prepared by stable transfection of MCF-7 cells with the human placental aromatase gene and Genetecin selection [48] [49] [50], was kindly provided by Dr. Shiuan Chen (Beckman Research Institute, City of Hope, Duarte, CA, U.S.A.). Cells were maintained with Eagles’s minimum essential medium (MEM) supplemented with Earle’s salts and 1 mmol/L sodium pyruvate, 1% penicillin-streptomycin-amphotericin B, 700 ng/ml G418 and 10% heat-inactivated fetal bovine serum (FBS) (Gibco) in 5% CO2 atmosphere at 37°C. To avoid the interference of steroids present in FBS and of the estrogenic effects of phenol-red [51], three days before starting the experiments, cells were cultured in an E2-free MEM medium without phenol-red containing 5% pre-treated charcoal heat-inactivated fetal bovine serum (CFBS). All the experiments were performed according to these conditions, with 1 nM of testosterone (T) (Sigma-Aldrich Co.), which was used as aromatase substrate and proliferation inducing agent and with or without exemestane (Sequoa Research Products Ltd.). The medium and drugs were refreshed every 3 days. Cells incubated with 1 nM of T plus 0.05% of DMSO (Sigma-Aldrich Co.) were used as control. All the assays were performed in triplicate in three independent experiments.

Morphological studies

The morphological alterations induced by exemestane were evaluated by phase contrast microscopy, Giemsa and Hoechst staining. After treatment, cells were fixed with 4% of paraformaldehyde (Sigma-Aldrich Co.). For Hoechst staining, cells were exposed to 0.5 mg/ml Hoechst 33258 (Sigma-Aldrich Co.) for 20 min and mounted with vectashield mounting medium. The nuclear morphology was examined under a fluorescence microscope (Eclipse E400, Nikon), equipped with an excitation filter with maximum transmission at 360/400 nm, and processed by Nikon ACT-2U image software. The Giemsa (Merck) stained cells were observed under the microscope Eclipse E400, Nikon equipped with image analysis software LeicaQwin.

Cell viability and cell proliferation

Cell viability was assessed by tetrazolium salt, 3-(4,5-di- methylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay and by measuring the lactate dehydrogenase (LDH) release. MCF-7aro cells were cultured in 96-well plates and incubated with different concentrations of exemestane during 2, 3, 6 and 9 days. Cells were also treated with 1 mM of 3-methyladenine (3-MA, Sigma-Aldrich Co.), an inhibitor of autophagy. After MTT (0.5 mg/ml) (Sigma-Aldrich Co.) addition, formazan was quantified spectrophotometrically. LDH release was measured using CytoTox 96 nonradioactive cytotoxicity assay kit (Promega Corporation) according to the manufacturer’s protocol.

To study the effects of exemestane on DNA synthesis, 3H-thymidine incorporation assay was performed. At each exposure time, 3H-thymidine (0.5 μCi) (Amersham) was added and incubated for the last 8 hours. Cells were harvested and, after addition of scintillation cocktail, 3H-thymidine incorporation was determined in a scintillation counter (LS 6500, Beckman Instruments). Results are expressed as relative percentage of the untreated control cells (100%).

Cell cycle analysis

To investigate the anti-proliferative effects of exemestane, cell cycle analysis was performed by flow cytometry. Cells were incubated with exemestane (2.5–10 μM) during 3 and 6 days, fixed with 70% cold ethanol and resuspended in 0.5 ml of DNA staining solution (5 μg/ml Propidium Iodide (PI), 0.1% Triton X-100 and 200 μg/ml DNase-free RNase A in PBS) (Sigma-Aldrich Co.) for 30 min. The three fluorescence channels (FL-1, FL-2 and FL-3) were set on a linear scale. The antiproliferative effect was indicated by the percentage of cells in G0/G1, S and G2/M phases of the cell cycle. Flow cytometric analysis was always based on the acquisition of 20 000 events in a Becton Dickinson FACSCalibur equipped with CELLQuest Pro software.

Analysis of apoptosis

To evaluate the translocation of phosphatidylserine (PS) to the cell surface, Annexin V-PE apoptosis detection Kit (BD Biosciences Pharmingen) was used. Mitochondrial transmembrane potential (∆Ψm) loss was studied using 3,3-dihexyloxacarbocyanine iodide (DiOC6(3) (Gibco) and flow cytometry analysis. Cells were cultured in 6-well plates and treated with exemestane (5–15 μM) during 3, 6 and 9 days. Adherent and non-adherent cells, after being pooled were incubated with the corresponding dye.

Cells were stained with Annexin V-PE and 7-amino-acitomycin (7-AAD), according to the manufacturer’s instructions. As positive control, cells were incubated with staurosporine (STS) (1 μM) (Sigma-Aldrich Co.) for 14 hours. Detectors for all three fluorescence channels (FL-1, FL-2 and FL-3) were set on a logarithmic scale. Bivariate analysis of Annexin-V/PE fluorescence (FL-2) and 7AAD fluorescence (FL-3) distinguished different cell populations, Annexin V+/7-AAD+ were designated as viable cells; Annexin V+/7-AAD− as apoptotic and Annexin V+/7-AAD− as late apoptotic and/or necrotic cells.

For ∆Ψm, cells were treated with exemestane or with 3-MA (1 mM) with or without exemestane, during 3 and 6 days. As positive control, cells were incubated with 10 μM of the mitochondrial depolarizant agent carbonyl cyanide m-chlorophenylhydrazide (CCCP) (Sigma-Aldrich Co.) and stained with DiOC6(3) (10 nM) for 30 min. PI (5 μg/ml) was added prior to
FACS analysis to discriminate among live cells that stain only with DiOC<sub>6</sub>(3), early apoptotic cells that lost the ability to accumulate DiOC<sub>6</sub>(3), and late apoptotic/necrotic cells that stain only with PI. Detectors were set on logarithmic scale, FL-1 was used to measure DiOC<sub>6</sub>(3) at green fluorescence and FL2 and FL-3 to measure PI red fluorescence.

Caspase-Glo® 9, Caspase-Glo® 8 and Caspase-Glo® 3/7 (Promega Corporation) are homogeneous luminescent assays that were used according to the manufacturer’s instructions. Cells were incubated with exemestane (10–15 μM) and with 3-MA (1 mM) plus exemestane for 3 days. As positive control, cells were incubated with STS (10 μM) for 3 hours and as negative control, cells with exemestane plus Z-VAD-FMK (50 μM). The resultant luminescence was measured in a 96-well Microplate Luminometer (BioTek Instruments) and presented as relative light units (RLU). It must be noted that as MCF-7 cells are known to be caspase-3 deficient [52], the use of Caspase-Glo® 3/7 kit only evaluates the activation of caspase-7.

**Intracellular reactive oxygen species (ROS) measurement**

To detect the levels of intracellular ROS the 2’,7’-dichlorodihydrofluorescein diacetate (DCFH<sub>2</sub>-DA) method was used. DCFH<sub>2</sub>-DA is a lipophilic non-fluorescent compound that crosses cell membrane and is oxidized to the fluorescent compound 2’-7’-dichlorofluorescein (DCF) [53]. Cells were incubated with exemestane (10–15 μM) and with 3-MA (1 mM) plus exemestane for 3 days. As positive control, cells were incubated with phorbol 12-myristate 13-acetate (PMA) (Sigma–Aldrich Co.) at 25 ng/ml for 2 hours. Cells were labeled with DCFH<sub>2</sub>-DA (50 μM) (Sigma–Aldrich Co.) for 1 hour at 37°C and fluorescence was measured using an excitation wavelength of 480 nm and an emission filter of 530 nm in a 96-well Microplate Luminometer and is presented as mean fluorescence intensity (MFI).

**Detection of acid vesicular organelles**

Acridine orange (AO) (Sigma–Aldrich Co.) was used to evaluate and quantify the formation of acid vesicular organelles (AVOs), by fluorescence microscopy and flow cytometry. AO is an acridotropic fluorescent dye that stain DNA and cytoplasm bright green (AO<sup>+</sup>) and when protonated in the presence of acid compartments it must be noted that as MCF-7 cells are known to be caspase-3 deficient and with or without 3-MA were cultured during 3 days in 6-well plates. After incubation, cells were lysed with cold TNTE lysis buffer (20 mM Tris-HCl, 150 mM NaCl, 0.3% Triton X-100 and 5 mM EDTA) (Sigma–Aldrich Co.), pH 7.5 containing appropriate protease inhibitors (Sigma–Aldrich Co.), and centrifuged at 18 800 g for 5 min at 4°C. Protein concentrations were determined using a Bradford assay kit (Bio-Rad). A total of 100 μg of protein per sample were subjected to 4–20% SDS-PAGE and transferred to nitrocellulose membranes. Immunodetection was performed using rabbit polyclonal antibody anti-LC3 (1:250) (Medical & Biological Laboratories) and the secondary peroxidase goat anti-rabbit antibody (1:5000) (Vector Laboratories). Immunoreactive bands were visualized using a chemiluminescent substrate Super Signal West Pico (Pierce). Membranes were then stripped and incubated with rabbit monoclonal anti-β-tubulin antibody (1:500) (Santa Cruz) to control loading variations.

**Statistical analysis**

The data presented are expressed as the mean ± SEM. Statistical analysis of data was performed using analysis of variance (ANOVA) followed by Bonferroni and Dunnet post-hoc tests for multiple comparisons. Values of P<0.05 were considered as statistically significant.

**Acknowledgments**

We thank Dr. Shinian Chen, City of Hope, Duarte, CA, USA for kindly supplying MCF-7aro cells and Dr. Rui Fernandes from IBMC for his help in electron microscopy studies.

**Author Contributions**

Conceived and designed the experiments: CA GCdS NT. Performed the experiments: CA SM. Analyzed the data: CA MB GCdS NT. Contributed reagents/materials/analysis tools: CA GGdS NT. Wrote the paper: ETdS GGdS NT. Revised the manuscript: ETdS GGdS NT. Read and approved the manuscript for publication: CA MB SM ETdS GGdS NT.

**References**

1. Macedo LF, Sabnis G, Brodie A (2009) Aromatase inhibitors and breast cancer. Ann N Y Acad Sci 1155: 162–173.
2. Gluck S (2010) Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer. Am J Clin Oncol 33: 314–319.
3. Fabian CJ (2007) The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer. Int J Clin Pract 61: 2051–2063.
4. Lunning PE (2009) Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? Eur J Cancer 45: 527–535.
5. Dutta U, Pant K (2008) Aromatase inhibitors: past, present and future in breast cancer therapy. Med Oncol 25: 113–124.
6. Miller WR, Bartlett J, Brodie AM, Brueggemeier RW, di Salle E, et al. (2008) Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist 13: 829–837.
7. Deeks ED, Scott LJ (2009) Exemestane: a review of its use in postmenopausal recurrent or metastatic breast cancer. Am J Clin Oncol 33: 314–319.
8. Dutta U, Pant K (2008) Aromatase inhibitors: past, present and future in breast cancer therapy. Med Oncol 25: 113–124.
9. Miller WR, Bartlett J, Brodie AM, Brueggemeier RW, di Salle E, et al. (2008) Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist 13: 829–837.
10. Deeks ED, Scott LJ (2009) Exemestane: a review of its use in postmenopausal cancer therapy. Med Oncol 25: 314–319.
11. Wang X, Chen S (2006) Aromatase inhibitor: novel action of exemestane, a food and drug administration-approved aromatase inhibitor. Cancer Res 66: 10281–10286.
9. Doisneau-Sixou SF, Sergio CM, Carroll JS, Hui R, Maugrove EA, et al. (2003) Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer 10: 179–186.

10. Gross JM, Yee D (2003) The type-1 insulin-like growth factor receptor tyrosine kinase and breast cancer: biology and therapeutic relevance. Cancer Metastasis Rev 22: 327–336.

11. Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, et al. (1994) Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat 29: 117–125.

12. Kyprianou N, English HF, Davidson NE, Isaacs JT (1991) Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res 51: 162–166.

13. Thiananawat A, Long BJ, Brodie AM (2003) Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Res 63: 8037–8050.

14. Dette S, Salter J, Barnes DM, Riddler S, Hills M, et al. (1999) Time-related effects of estrogen withdrawal on proliferation- and cell death-related events in MCF-7 xenografts. Int J Cancer 81: 309–313.

15. Truchet I, Jozan S, Guermin M, Mazzolini L, Vidal S, et al. (2000) Interconnections between E2-dependent regulation of cell cycle progression and apoptosis in MCF-7 tumors growing on nude mice. Exp Cell Res 254: 241–248.

16. Kalla A, Zheng A, Dahllund H, Heiskanen KM, Harkonen P (2005) Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells. Apoptosis 10: 1395–1410.

17. Nazarredez RR, Zenecke WJ, Parikh A, Larson SK, Alderson E, et al. (2007) Tamoxifen induces oxidative stress and mitochondrial apoptosis via stimulating mitochondrial nitric oxide synthase. Cancer Res 67: 1282–1290.

18. Lin KB, Ng CY, Ong CK, Ong CS, Tran E, et al. (2000) Induction of apoptosis in mammalian cells by a pure anti-estrogen ICI 182780. Breast Cancer Res Treat 68: 127–138.

19. Samadkar JS, Gaddy VT, Duplanter J, Thandavan SP, Shah M, et al. (2008) A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance. Mol Cancer Ther 7: 2977–2987.

20. Qadir MA, Kwok B, Dragowska WH, To KH, Le D, et al. (2008) Macrophage inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization. Breast Cancer Res Treat 112: 389–403.

21. de Medina P, Payre B, Boubekeur N, Bertrand-Michel J, Tercé F, et al. (2009) Ligands of the antiestrogen-binding site induce active cell death and apoptosis in human breast cancer cells through the modulation of cholesterol metabolism. Cell Death Differ 16: 1372–1384.

22. de Medina P, Silvente-Poirat S, Poirat M (2009) Tamoxifen and AEBs ligands induced apoptosis and autophagy in breast cancer cells through the stimulation of sterol accumulation. Autophagy 5: 1066–1067.

23. Itoh T, Karshberg K, Kijima I, Yuan YC, Smith D, et al. (2005) Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7/aro cells: a microarray approach. Mol Cancer Res 3: 203–210.

24. Cepa MM, Tavares da Silva EJ, Correia-da-Silva G, Rolêrma FR, Teixeira NA (2005) Structure-activity relationships of new AD-ring modified steroids as aromatase inhibitors: design, synthesis, and biological activity evaluation. J Med Chem 48: 6379–6385.

25. Cepa M, Correia-da-Silva G, Tavares da Silva EJ, Rolêrma FR, Hong Y, et al. (2008) Molecular mechanisms of aromatase inhibition by new A, D-ring modified steroids. Biol Chem 389: 1183–1191.

26. Cepa M, Correia-da-Silva G, da Silva EJ, Rolêrma FR, Borges M, et al. (2008) New steroidal aromatase inhibitors: suppression of estrogen-dependent breast cancer cell proliferation and induction of cell death. BMC Cell Biol 9: 41.

27. Chen Y, Azad MB, Gibson SB (2010) Methods for detecting autophagy and determining autophagy-induced cell death. Curr J Physiol Pharmacol 88: 285–295.

28. Paglin S, Hollister T, Delohery T, Hackett N, McMahlil M, et al. (2001) A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res 61: 490–444.

29. DiPaola RS (2002) To arrest or not to G2/M cell-cycle arrest: commentary re: A. K. Tyagi et al., Stibbim strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G2/M arrest, and apoptosis. Clin. cancer res., 8: 3512–3519, 2002. Clin Cancer Res 8: 3311–3314.

30. Kroemer G, Galluzzi L, Brenner C (2007) Mitochondrial membrane permeabilization in cell death. Physiol Rev 87: 99–163.

31. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, et al. (2008) Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4: 151–172.

32. Marden DT, Eger II, Bredesen DE (2007) A calpain-like protease inhibits autophagic cell death. Autophagy 3: 519–522.

33. Lemasters JJ, Qian T, He L, Kim JS, Elmoor SP, et al. (2002) Role of mitochondrial inner membrane permeabilization in necrotic cell death, apoptosis, and autophagy. Antioxid Redox Signal 4: 769–781.

34. Dewaele M, Maes H, Agostinis P (2010) ROS-mediated mechanisms of autophagy stimulation and their relevance in cancer therapy. Autophagy 6: 838–854.

35. Hou W, Han J, Lu C, Goldstein LA, Rabinovich H (2010) Autophagic degradation of active caspase-II: a crosstalk mechanism between autophagy and apoptosis. Autophagy 6: 991–990.

36. Fereira CG, Span SW, Peters GJ, Kwiat FA, Giaccone G (2000) Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res 60: 7133–7141.

37. de Vries JJ, Wamases JJ, Fedema I, van Deuren L, Nijmeijer BA, et al. (2007) Involvement of caspase-8 in chemotherapy-induced apoptosis of patient derived leukemia cell lines independent of the death receptor pathway and downstream from mitochondria. Apoptosis 12: 181–193.

38. Boys P, Gonzalez-Polo RA, Casares N, Perfettini JL, Dessen P, et al. (2005) Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol 25: 1025–1040.

39. Eisenberg-Lerner A, Balik S, Simon HU, Kimchi A (2009) Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ 16: 966–975.

40. Eisenberg-Lerner A, Kimchi A (2009) The paradox of apoptosis and its implication in cancer etiology and therapy. Apoptosis 14: 376–391.

41. Sun WL, Chen J, Wang YP, Zheng H (2011) Autophagy protects breast cancer cells from epirubicin-induced apoptosis and facilitates epirubicin-resistance development. Autophagy 7: 1035–1044.

42. Kainematsu S, Uehara N, Miki H, Yoshizawa K, Kawamura A, et al. (2010) Autophagy inhibition enhances sulforaphane-induced apoptosis in human breast cancer cells. Anticancer Res 30: 3381–3390.

43. Abedin MJ, Wang D, McDonnell MA, Lehmann U, Kelekar A (2007) Autophagy delays apoptotic death in breast cancer cells following DNA damage. Cell Death Differ 14: 500–510.

44. Yan CH, Yang VP, Qin ZH, Gu ZL, Reil P, et al. (2007) Autophagy is involved in cytotoxic effects of crototox in human breast cancer cell line MCF-7 cells. Acta Pharmacol Sin 26: 540–548.

45. Lemasters JJ (1998) The mitochondrial permeability transition: from biochemical curiosity to pathophysiological mechanism. Gastroenterology 115: 783–786.

46. Zhivotovsky B, Orrenius S (2010) Cell death mechanisms: cross-talk and role in disease. Exp Cell Res 316: 1374–1383.

47. Gozuacik D, Kimchi A (2004) Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23: 2891–2906.

48. Zhou DJ, Pompon D, Chen SA (1990) Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res 50: 6949–6954.

49. Sun XZ, Zhou D, Chen S (1997) Autocrine and paracrine actions of breast cancer cells. Oncology 22: 327–336.

50. Berthois Y, Katzenellenbogen BS (1986) Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci U S A 83: 2496–2500.